# US 2004/0082591 A1 · Therapeutic heterocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082591 A1
- Document ID: US20040082591A1
- Status: Published application
- Kind: A1
- Application number: 10/466,540
- Filed: 2003-07-16
- Published: 2004-04-29
- Earliest claimed: 2001-11-01
- Inventors: Marc Chapdelaine; Timothy Davenport; Markus Haeberlein; Carey Horchler; John McCauley; Edward Pierson; Daniel Sohn
- Web page: https://patentgrep.com/patent/US20040082591A1

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 215/50: attached in position 4
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 311/24: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein is a compound having the formula (I) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

## Claims

### Claim 1

A compound having the formula (I):
258
wherein
R1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, thiomethoxy, —NHA, —NA2, —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA2, halogen, hydroxy, —OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;
R2is represented by (i), (ii), (iii), or (iv) below:
259
R3 is independently at each position represented by —H, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-6cycloalkyl or AOH;
n is 2, 3 or 4;
P is a heterocyclic ring;
R4 is —H or optionally substituted C1-4alkyl;
R5 is —H, ═O, —OR4, —NR42=NR4, —SR4 or ═S;
R6 is —H or methyl;
X is O, N, NH or S;
Y is —C(═O)NH—, —C(═O)NA—, —C(═O)N(A)—, —NHC(═O)—, —C(═S)NH—, —CH2NH—, —C(═O)—, —C(═O)CH2—, —CH2C(═O)—, —C(═O)—piperazine-,, —NAC(═O)—, —C(═S)N(A)—, CH2NA, NACH2 or a 5-membered heterocyclic;
R7 is a monocyclic or bicyclic aromatic ring or a heterocycle optionally substituted by one or more substituents selected from R8-R9 and R10; wherein R7 is connected to Y either by a single bond as tether, or by a ring fusion comprising a bond and two ring atoms shared by both rings;
R8 is —CH2—, —C(═O)—, —SO2—, —SO2NH—, —C(═O)NH—, —O—, —S—, —S(═O)— a single bond as tether from R7 to R9,or a five-membered heterocyclic connected to R7 by a ring fusion comprising a bond and two ring atoms shared by both rings, or a single bond as tether;
R9 is optionally substituted heterocycle, optionally substituted aryl, optionally substituted piperazinyl-R11, optionally substituted morpholinyl-R11, optionally substituted thiomorpholinyl, C(═O)A;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen, —C(═O)NH2, methylthio, —NHA, —NA2, —NHC(═O)A, —C(═O)NHA, —C(═O)NA2, or —OA;
R11 is —H, alkyl, AOH, —SO2A, —SO2NH2, —SO2NHA, —SO2NA2, —SO2NHAR9, —C(═O)R9, -alkylR9, C(═O)A, C(═O)NH2, C(═O)NHA, C(═O)NA2 or —C(═O)OA; or a pharmaceutically acceptable salt thereof; and
260
represents a bond which may be either a single bond or a double bond, with the proviso that multiple double bonds are separated from one another by at least one single bond.

### Claim 2 (depends on 1)

A compound of formula I as recited in claim 1 for use in the treatment of depression, generalized anxiety, eating disorders, dementia, panic disorder, sleep disorders, gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm and sexual dysfunction of an animal in need of such therapy.

### Claim 3

A method of treatment of a human or animal suffering from depression, generalized anxiety, eating disorders, dementia, panic disorder, sleep disorders, gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm and sexual dysfunction administering to such animal an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV or Formula V or a pharmaceutically acceptable salt of said compound.

### Claim 4 (depends on 1)

the use of a compound of formula I as recited in claim 1 in the preparation of a medicament for the treatment of depression, generalized anxiety, eating disorders, dementia, panic disorder, sleep disorders, gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm and sexual dysfunction.

### Claim 5

A compound of the Formula (Vie):
261
wherein R1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, —NHA, —NA2, —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA2, halogen, hydroxy, —OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;
R2is represented by (i), (ii), (iii), or (iv) below:
262
and X is represented by O, S, N, or NH; or a pharmaceutically acceptable salt of said compound.

### Claim 6

The compound of Formula (VIf):
263
wherein R1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, —NHA, —NA2, —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA2, halogen, hydroxy, —OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:
264
and X is represented by O, S, N, or NH; or a pharmaceutically acceptable salt of said compound.

### Claim 7

A compound of Formula (VIg)
265
wherein R1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, —NHA, —NA2, —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA2, halogen, hydroxy, —OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;
L represents a leaving group.
R2 is represented by (i), (ii), (iii), or (iv) below:
266
and X is represented by O, S, N or NH; or a pharmaceutically acceptable salt of said compound.

### Claim 8

A compound of Formula (VIh)
267
wherein R1 is, at each position, independently represented by hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, methoxy, thiomethoxy, —NHA, —NA2, —NHC(═O)A, aminocarbonyl, —C(═O)NHA, —C(═O)NA2, halogen, hydroxy, —OA, cyano or aryl;
A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl;
R2 is represented by (i), (ii), (iii), or (iv) below:
268
and X is represented by O, S, N, or NH; or a pharmaceutically acceptable salt of said compound.

### Claim 9 (depends on 5)

A process for preparing a compound of Formula (VIe) as recited in claims 5 comprising reacting a compound of Formula (VId):
269
with HR2 in the presence of a catalyst and a base.

### Claim 10 (depends on 6, 45)

A process for preparing a compound of Formula (VIf) as recited in claim 6 comprising heating a compound a of Formula (VIe) as recited in claim 45 in the presence of an acid and water.

### Claim 11 (depends on 7)

A process for preparing a compound of Formula (VIg) as recited in claim 7 comprising replacing the hydroxyl group of the carboxyl ate moiety of Formula (VIg) with a leaving group.

### Claim 12 (depends on 6, 8)

A process for preparing a compound of Formula (VIh) as recited in claim 8 comprising reacting a compound of (VIf) as recited in claim 6 with H2R7, wherein R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted by one or more substituents selected from R8-R9 and R10; wherein R7 is connected to Y either by a single bond or by a ring fusion;
R8 is —CH2—, —C(═O)—, —SO2—, —SO2NH—, —C(═O)NH—, —O—, —S—, —S(═O)—, a five membered heterocyclic connected to R7 by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected from A, thiomoipholine, piperazin-R11, optionally substituted aryl, optionally substituted heterocyclic, or —C(═O)CA;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen, —C(═O)NH2—, methylthio, —NHA, —NA2, —NHC(═O)A, —C(═O)NHA, —C(═O)NA2, or OA;
R11 is —H, alkyl, AOH, —SO2A, —SO2NH2, —SO2NHA, —SO2NA2, —SO2NHAR9, —C(═O)R9, -alkylR9, C(═O)A, C(═O)NH2, C(═O)NHA, C(═O)NA2 or —C(═O)OA.

### Claim 13 (depends on 8)

A process for preparing a compound of Formula (VIh) as recited in claim 8 comprising reacting a compound of Formula (VIg) with H2R7 wherein R7 is a monocyclic or bicyclic aromatic ring or a heterocycle, optionally substituted by one or more substituents selected from R8-R9 and R10; wherein R7 is connected to Y either by a single bond or by a ring fusion;
R8 is —CH2—, —C(═O)—, —SO2—, —SO2NH—, —C(═O)NH—, —O—, —S—, —S(═O)—, a five membered heterocyclic connected to R7 by a ring fusion or single bond as tether;
R9 is morpholine optionally substituted with at least one substituent selected from A, thiomorpholine, piperazin-R11, optionally substituted aryl, optionally substituted heterocyclic, or —C(═O)CA;
R10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen, —C(═O)NH2—, methylthio, —NHA, —NA2, -NHC(═O)A, —C(═O)NHA, —C(═O)NA2, or OA;
R11 is —H, alkyl, AOH, —SO2A, —SO2NH2, —SO2NHA, —SO2NA2, —SO2NHAR9, —C(═O)R9, -alkylR9, C(═O)A, C(═O)NH2, C(═O)NHA, C(═O)NA2 or —C(═O)OA.
